(NP (NP (NN Hypertension)) (PP (IN in) (NP (NN pregnancy))) (. .))
(S (NP-SBJ (NP (JJ Pregnancy-induced) (NN hypertension)) (PRN (-LRB- -LRB-) (NP (NN PIH)) (-RRB- -RRB-))) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ frequent) (NN cause)) (PP (IN of) (NP (ADJP-COOD (ADJP (JJ maternal)) (CC and) (ADJP (JJ neonatal))) (NP-COOD (NP (NN morbidity)) (CC and) (NP (NN mortality))))))) (. .))
(S (PP (IN In) (NP (DT the) (JJ present) (NN study))) (NP-SBJ (PRP we)) (VP (VBD focused) (PP (PP (IN on) (NP (NP (DT the) (NN pathophysiology)) (PP (IN of) (NP (NN PIH))))) (, ,) (PP (RB mainly) (IN on) (NP-COOD (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NNS mineralocorticoids)))) (, ,) (NP (VBN reversed) (NN blood) (NN pressure) (NNS patterns)) (, ,) (CC and) (NP (NP (DT the) (VBG resulting) (NN necessity)) (PP (IN of) (NP (NP (JJ continuous) (NN monitoring)) (PP (IN of) (NP (DT the) (JJ preeclamptic) (NN mother)))))))))) (. .))
(S-COOD (S (NP-SBJ-52 (NP (NNS Problems)) (PP (IN of) (NP (JJ antihypertensive) (NN therapy)))) (VP (VBP are) (VP (VBN discussed) (NP (-NONE- *-52))))) (CC and) (S (NP-SBJ-53 (NP (DT the) (JJ first) (NNS results)) (PP (IN of) (NP (NP (DT a) (NN pilot) (NN study)) (PP (IN with) (NP (NN Urapidil)))))) (VP (VBP are) (VP (VBN presented) (NP (-NONE- *-53))))) (. .))
(S (S (NP-SBJ (-NONE- *-54)) (VP (TO To) (VP (VB examine) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NNS mineralocorticoids))) (PP (IN in) (NP (NP (DT the) (NN pathophysiology)) (PP (IN of) (NP (NN PIH))))))))) (, ,) (NP-SBJ-54 (PRP we)) (VP (VBD studied) (NP (NP (NP-COOD (NP (NN plasma) (NN aldosterone)) (CC and) (NP (NP (NN 18-hydroxy-corticosterone)) (PRN (-LRB- -LRB-) (NP (NN 18-OH-B)) (-RRB- -RRB-)))) (NNS levels)) (PP-COOD (PP (IN in) (NP (NP (CD 25) (NNS women)) (PP (IN with) (NP (NN PIH))))) (CC and) (PP (IN in) (NP (CD 25) (JJ healthy) (JJ pregnant) (NNS women)))))) (. .))
(S (ADVP (RB Furthermore)) (, ,) (NP-SBJ (PRP we)) (VP (VBD evaluated) (NP (NP (NP (NP (DT the) (NN mineralocorticoid) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN MR)) (-RRB- -RRB-))) (NN count)) (PP (IN in) (NP (NP (JJ mononuclear) (NNS leukocytes)) (PP (IN in) (NP (DT the) (CD 2) (NNS groups))))))) (. .))
(S (NP-SBJ-55 (DT The) (NN MR-count)) (VP (VBD was) (ADVP (RB significantly)) (VP (VBN decreased) (NP (-NONE- *-55)) (PP (IN in) (NP (DT the) (NN PIH-group))))) (. .))
(S (NP-SBJ (NP (DT The) (NNS values)) (PP (IN of) (NP-COOD (NP (NN plasma) (NN aldosterone)) (CC and) (NP (NN 18-OH-B))))) (VP (VBD were) (ADVP (RB also)) (ADJP-PRD (JJ low))) (. .))
(S (NP-SBJ-56 (DT These) (NNS results)) (VP (MD can) (RB not) (VP (VB be) (VP (VBN explained) (NP (-NONE- *-56)) (PP (IN by) (NP-LGS (NP (NN receptor) (NN down-regulation)) (PP (JJ due) (TO to) (NP (NP (JJR higher) (NN level)) (PP (IN of) (NP (NP (NNS mineralocorticoids)) (PP (IN of) (NP (DT the) (NN zona) (NN glomerulosa)))))))))))) (. .))
(S (ADVP (RB Perhaps)) (NP-SBJ-COOD (NP (NN deoxycorticosterone)) (CC or) (NP (DT a) (RB hitherto) (JJ unknown) (NN mineralocorticoid))) (VP (VBZ is) (ADJP-PRD (JJ responsible) (PP (IN for) (NP (DT the) (NP-COOD (NP (NN hypertension)) (CC and) (NP (JJ altered) (NN MR-status))))))) (. .))
(S (NP-SBJ-57 (NP (DT The) (JJ first) (NNS results)) (PP (IN of) (NP (NP (JJ continuous) (NN blood) (NN pressure) (NNS measurements)) (PP (IN with) (NP (NP (DT a) (ADJP-COOD (ADJP (JJ noninvasive)) (, ,) (ADJP (JJ real-time))) (NN blood) (NN pressure) (NN monitor)) (PRN (-LRB- -LRB-) (NP (NN Finapres)) (-RRB- -RRB-))))))) (VP (VBP are) (VP (VBN presented) (NP (-NONE- *-57)))) (. .))
(S (NP-SBJ (NP (DT The) (NN comparison)) (PP (IN of) (NP (DT the) (VBN obtained) (NNS values))) (PP (IN with) (NP (JJ intraarterial) (NNS measurements)))) (VP (VBZ demonstrates) (NP (NP (DT a) (JJ good) (NN correlation)) (PP (IN between) (NP (DT the) (CD two) (NNS methods))))) (. .))
(S (NP-SBJ (PRP We)) (ADVP (RB also)) (VP (VBP report) (PP (IN on) (NP (NP (DT the) (JJ first) (NNS experiences)) (PP (IN with) (NP (NN Urapidil))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NN hypertension)) (PP (IN in) (NP (JJ severe) (NN preeclampsia)))))))))) (. .))
(S (NP-SBJ (DT The) (NNS data)) (VP (VBP show) (SBAR (IN that) (S (NP-SBJ-59 (NP (NN hypertension)) (PP (IN in) (NP (JJ preeclamptic) (NNS women)))) (VP (MD can) (VP (VB be) (VP (VBN treated) (NP (-NONE- *-59)) (PP (IN by) (NP-LGS (NN Urapidil))) (PP (IN without) (NP-COOD (NP (JJ side) (NNS effects)) (CC or) (NP (NN reflex-tachycardia)))))))))) (. .))
(S (NP-SBJ-60 (JJ Further) (NNS studies)) (VP (MD will) (VP (VB have) (S (NP-SBJ (-NONE- *-60)) (VP (TO to) (VP (VB prove) (SBAR (IN if) (S (NP-SBJ (NN Urapidil)) (VP (VBZ is) (ADJP-PRD (VBN suited) (PP (IN for) (NP (NP (JJ prepartal) (NN treatment)) (PP (IN of) (NP (NN PIH))))) (ADVP (RB as) (RB well))))))))))) (. .))
